Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Active Psoriatic Arthritis Clinical Trial

Official title:

A Multicenter, Open-Label Study to Evaluate the Safe and Effective Use of an Electro-Mechanical Injection Device (E-Device) for the Subcutaneous Self-Injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03357471
• Other study ID #: RA0098
• Status: Completed
• Phase: Phase 3
• Start date: November 3, 2017
• Est. completion date: July 2, 2018

Study information

• Verified date: October 2019
• Source: UCB Pharma
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the ability of subjects who are already prescribed Certolizumab Pergol therapy and have been self injecting with prefilled syringes for at least the previous three months, to safely and effectively self-inject Certolizumab Pegol (CZP) using the e-Device and to evaluate the post-use structural integrity of used devices and cassettes via visual examination.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: July 2, 2018
• Est. primary completion date: July 2, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject is male or female and must be at least 18 years old at Visit 1

• Subject must have been diagnosed at least 6 months prior to Visit 1 with documented moderate to severe active Rheumatoid Arthritis (RA), active Psoriatic Arthritis (PsA), active Ankylosing Spondylitis (AS) (in US), or moderately to severely active Crohn's Disease (CD) (in US)

• A minimum of 10 subjects will have impaired hand function. Impaired hand function will be measured using the Cochin scale (Duruöz et al, 1996; Poiraudeau et al, 2000) and impaired hand function will be defined as patients who have a Cochin score >= 13.5 at Baseline

• Subjects must have been prescribed Certolizumab Pegol (CZP) and must have been self-injecting CZP using the pre-filled syringe for at least 3 months prior to Visit

1. Subjects with RA, PsA, or AS must have been on a stable Q2W (every 2 weeks) or Q4W (every 4 weeks) CZP dosing regimen for at least 3 months prior to Screening. Subjects with CD must have been on a stable Q4W CZP dosing regimen for at least 3 months prior to Visit 1.

• Subjects must have been screened according to the applicable national tuberculosis (TB) screening guidelines (to be documented) or provide a documented TB screening activity (TB questionnaire, Interferon-Gamma-Release Assay (IGRA) test, or chest x-ray) within the past 12 months prior to Visit 1.

• Female subjects of childbearing potential should have a negative pregnancy test at Visit 1 and should be using a medically accepted method of contraception during the entire duration of the study. Female subjects who are postmenopausal for at least 2 years or have undergone a complete hysterectomy, bilateral tubal ligation, and/or bilateral oophorectomy, or have a congenital sterility are considered not of childbearing potential

Exclusion Criteria:

• Subject has participated in another study of an investigational medicinal product (IMP) or an investigational device within the previous 3 months or is currently participating in another study of an IMP or an investigational device

• Subject has a history of chronic alcohol or drug abuse within the previous 6 months

• Subject has a history of significant cardiovascular, respiratory, gastrointestinal, hepatic, endocrine, renal, dermatological, neurological, psychiatric, hematological, or bleeding disorders

• Subjects with known Tuberculosis (TB) infection and at high risk of acquiring TB infection. Subjects with latent TB (LTB) who have not completed the prophylactic treatment regimen for LTB 3 months prior to enrollment

• Subject has an active chronic/latent infection including but not limited to TB (untreated latent or active), hepatitis virus (HV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)

• Subject has a current malignancy or a history of malignancy. Subjects with less than 3 completely excised basal cell carcinomas or with cervical carcinoma in situ successfully treated surgically more than 5 years prior to Screening may be included

• Subject has had major surgery (including joint surgery) within 8 weeks prior to Visit 1, or has a scheduled surgery during the study

Related Conditions & MeSH terms

• Active Ankylosing Spondylitis
• Active Psoriatic Arthritis
• Arthritis
• Arthritis, Psoriatic
• Arthritis, Rheumatoid
• Crohn Disease
• Moderate and Severe Active Rheumatoid Arthritis
• Moderately to Severely Active Crohn's Disease
• Spondylitis
• Spondylitis, Ankylosing

Intervention

Drug:
• e-Device
Active Substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Route of administration: subcutaneous injection by e-Device

Locations

Country	Name	City	State
United States	Ra0098 102	Austin	Texas
United States	Ra0098 111	Austin	Texas
United States	Ra0098 123	Austin	Texas
United States	Ra0098 131	Clermont	Florida
United States	Ra0098 122	Clive	Iowa
United States	Ra0098 132	Coral Springs	Florida
United States	Ra0098 128	Corpus Christi	Texas
United States	Ra0098 101	Covina	California
United States	Ra0098 103	Dover	New Jersey
United States	Ra0098 127	Gainesville	Georgia
United States	Ra0098 117	Great Neck	New York
United States	Ra0098 126	Hixson	Tennessee
United States	Ra0098 107	Mesa	Arizona
United States	Ra0098 116	Mesa	Arizona
United States	Ra0098 113	Myrtle Beach	South Carolina
United States	Ra0098 106	Nassau Bay	Texas
United States	Ra0098 135	Phoenix	Arizona
United States	Ra0098 133	Richland	Washington
United States	Ra0098 104	Saint Louis	Missouri
United States	Ra0098 105	Saint Louis	Missouri
United States	Ra0098 114	San Antonio	Texas
United States	Ra0098 119	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
UCB Biopharma S.P.R.L.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 2	Safe and effective self-injection was evaluated by the healthcare provider and is defined as: Dose Delivery: Subject self-injected the complete dose of Certolizumab Pegol (CZP) as confirmed by a visual inspection of the CZP-cassette(s) which shows the pre-filled syringe container to be empty AND; No Adverse Events related to use of the e-Device (Adverse Device Effects) that would preclude continued use of the e-Device for self-injection.; For subjects on the Q4W (every 4 weeks) dosing regimen who would self-inject twice (2×200 mg CZP) at each visit, each injection was evaluated for safety and effectiveness using the above criteria. The primary endpoint of safe and effective self-injection for subjects on the Q4W dosing regimen was met only if both self-injections were determined to be safe and effective.	Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Secondary	Percentage of Subjects Able to Self-administer Safe and Effective Injections Using the e-Device at Visit 1	Safe and effective self-injection was evaluated by the healthcare provider and is defined as: Dose Delivery: Subject self-injected the complete dose of Certolizumab Pegol (CZP) as confirmed by a visual inspection of the CZP-cassette(s) which shows the pre-filled syringe container to be empty AND; No Adverse Events related to use of the e-Device (Adverse Device Effects) that would preclude continued use of the e-Device for self-injection.; For subjects on the Q4W (every 4 weeks) dosing regimen who would self-inject twice (2×200 mg CZP) at each visit, each injection was evaluated for safety and effectiveness using the above criteria. The primary endpoint of safe and effective self-injection for subjects on the Q4W dosing regimen was met only if both self-injections were determined to be safe and effective.	Visit 1 (Week 0)
Secondary	Percentage of Used Certolizumab Pegol (CZP)-Cassettes Identified as Having Structural Integrity Issues Based on Visual Examination	CZP-cassettes identified as having structural integrity issues meant CZP-cassettes with clear evidence of damage/compromised structural integrity, not superficial cosmetic imperfections.	During the study (from Week 0 up to Week 4)
Secondary	Mean Change From Baseline in Systolic Blood Pressure	Blood pressure was measured in millimetre of mercury (mmHg).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Secondary	Mean Change From Baseline in Diastolic Blood Pressure	Blood pressure was measured in millimetre of mercury (mmHg).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Secondary	Mean Change From Baseline in Pulse Rate	Pulse Rate was measured in beats per minute (beats/min).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Secondary	Mean Change From Baseline in Respiratory Rate	Respiratory Rate was measured in breaths per minute (breaths/min).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Secondary	Mean Change From Baseline in Body Temperature	Body Temperature was measured in Grad Celsius (°C).	From Week 0 to Visit 2 (Week 2 for Q2W; Week 4 for Q4W)
Secondary	Incidence of Adverse Events (AEs) During the Study	An Adverse Event (AE) was any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product that did not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of investigational medicinal product (IMP), whether or not related to the medicinal (investigational) product.	During the study (from Week 0 up to Week 5 +/-3 Days)
Secondary	Incidence of Adverse Device Events (ADEs) During the Study	An Adverse Device Event (ADE) was an AE related to the use of an investigational device. An ADE must have met 1 or more of the following criteria: Adverse event that resulted from insufficiencies or inadequacies in the Instructions for Use (IFU), the deployment, the implantation, the installation, the operation, or any malfunction of the investigational medical device; Adverse event that was a result of an error or intentional misuse.	During the study (from Week 0 up to Week 5 +/-3 Days)

External Links

•   FDA Safety Alerts and Recalls
•   Product Information